Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Melphalan Conditioning for ASCT in Multiple Myeloma
NCT00642395Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jul 2007
- Primary completion
- Oct 2008
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Complete Response and Very Good Partial Response rates at 3 months. Started Jul 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00642395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00642395.